TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (TLSI)
CUSIP: 89680M101
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 61,418,480
- Total 13F shares
- 2,947,768
- Share change
- +605,712
- Total reported value
- $16,271,736
- Price per share
- $5.52
- Number of holders
- 33
- Value change
- +$3,567,159
- Number of buys
- 22
- Number of sells
- 6
Quarterly Holders Quick Answers
What is CUSIP 89680M101?
CUSIP 89680M101 identifies TLSI - TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 89680M101:
Top shareholders of TLSI - TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MedTech Acquisition Sponsor LLC |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
6,250,000
mixed-class rows
|
$65,538,115 | — | 26 Jun 2023 | |
| Wealthcare Advisory Partners LLC |
13F
|
Company |
1%
|
643,740
|
$3,225,137 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.78%
|
476,292
|
$2,386,223 | — | 31 Dec 2024 | |
| Duquesne Family Office LLC |
13F
|
Company |
0.7%
|
426,921
|
$2,139,000 | — | 31 Dec 2024 | |
| George Kelly Martin |
3/4/5
|
Director |
—
mixed-class rows
|
262,176
mixed-class rows
|
$1,359,468 | — | 28 Aug 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.33%
|
204,137
|
$1,023,028 | — | 31 Dec 2024 | |
| Graypoint LLC |
13F
|
Company |
—
class O/S missing
|
827,590
|
$910,349 | — | 31 Dec 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.29%
|
178,446
|
$894,015 | — | 31 Dec 2024 | |
| James Alecxih |
3/4/5
|
President, Device Technology |
—
class O/S missing
|
94,754
|
$521,147 | — | 10 Aug 2023 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.13%
|
80,538
|
$403,495 | — | 31 Dec 2024 | |
| Steven C. Katz |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
173,587
mixed-class rows
|
$377,229 | — | 12 Feb 2024 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.11%
|
65,000
|
$325,650 | — | 31 Dec 2024 | |
| Vestcor Inc |
13F
|
Company |
—
mixed-class rows
|
94,208
mixed-class rows
|
$206,000 | — | 31 Dec 2024 | |
| MSD Partners, L.P. |
13F
|
Company |
0.07%
|
39,999
|
$200,395 | — | 31 Dec 2024 | |
| Magnetar Financial LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
16,668
|
$174,782 | — | 12 Jun 2023 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.05%
|
32,112
|
$160,881 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.05%
|
30,270
|
$151,653 | — | 31 Dec 2024 | |
| Connective Capital Management, LLC |
13F
|
Company |
0.05%
|
27,989
|
$140,225 | — | 31 Dec 2024 | |
| Connecticut Wealth Management, LLC |
13F
|
Company |
0.04%
|
22,303
|
$111,738 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.03%
|
20,200
|
$101,202 | — | 31 Dec 2024 | |
| Cambridge Investment Research Advisors, Inc. |
13F
|
Company |
0.03%
|
15,554
|
$78,000 | — | 31 Dec 2024 | |
| GILDER GAGNON HOWE & CO LLC |
13F
|
Company |
0.02%
|
14,420
|
$72,244 | — | 31 Dec 2024 | |
| Lido Advisors, LLC |
13F
|
Company |
0.02%
|
14,024
|
$70,260 | — | 31 Dec 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.02%
|
13,400
|
$67,134 | — | 31 Dec 2024 | |
| ANGELO GORDON & CO., L.P. |
13F
|
Company |
0.02%
|
10,854
|
$54,379 | — | 31 Dec 2024 | |
| Liselotte Hyveled |
3/4/5
|
Director |
—
mixed-class rows
|
60,040
mixed-class rows
|
$39,859 | — | 02 Jan 2025 | |
| B & T Capital Management DBA Alpha Capital Management |
13F
|
Company |
—
class O/S missing
|
22,222
|
$24,445 | — | 31 Dec 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
—
class O/S missing
|
21,253
|
$23,000 | — | 31 Dec 2024 | |
| Foster Victor Wealth Advisors, LLC |
13F
|
Company |
—
class O/S missing
|
18,328
|
$22,177 | — | 31 Dec 2024 | |
| WOLVERINE ASSET MANAGEMENT LLC |
13F
|
Company |
—
mixed-class rows
|
14,932
mixed-class rows
|
$20,460 | — | 31 Dec 2024 | |
| Exos Asset Management LLC |
13F
|
Company |
0.01%
|
3,604
|
$18,056 | — | 31 Dec 2024 | |
| Richard Charles Hoertkorn |
13F
|
Individual |
0%
|
668
|
$3,347 | — | 31 Dec 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
mixed-class rows
|
597
mixed-class rows
|
$2,827 | — | 31 Dec 2024 | |
| SIGNATUREFD, LLC |
13F
|
Company |
0%
|
100
|
$501 | — | 31 Dec 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
79
|
$395 | — | 31 Dec 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
24
|
$120 | — | 31 Dec 2024 | |
| CLEAR STREET LLC |
13F
|
Company |
—
class O/S missing
|
100
|
$110 | — | 31 Dec 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
22
|
$110 | — | 31 Dec 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
1
|
$5 | — | 31 Dec 2024 | |
| Andrew C. von Eschenbach |
3/4/5
|
Director |
—
mixed-class rows
|
50,000
mixed-class rows
|
— | — | 13 Aug 2024 | |
| Anil K. Singhal |
3/4/5
|
Director |
—
class O/S missing
|
15,000
|
— | — | 13 Aug 2024 |
Institutional Holders of TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (TLSI) as of Q1 2025
As of 31 Mar 2025,
TriSalus Life Sciences, Inc. - Common Stock, $0.01 par value (TLSI) was held by
33 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,947,768 shares.
The largest 10 holders included
GILDER GAGNON HOWE & CO LLC, Wealthcare Advisory Partners LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BANK OF AMERICA CORP /DE/, MILLENNIUM MANAGEMENT LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, MSD Partners, L.P., NORTHERN TRUST CORP, and GOLDMAN SACHS GROUP INC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
28
Q1 2025 holders
33
Holder diff
5
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.